about CAR T

Our mission is to develop CAR T therapies that produce a better and more durable response than previous CAR T generations, improving treatment outcomes and saving the lives of patients with refractory cancers.


Join us at the 4th Annual Next Gen Immuno-Oncology Virtual Congress where our CSO, Dr John Maher, will be talking about CAR T-cell immunotherapy of solid tumours.

CAR T-Cell Immunotherapy of Solid Tumours: Parallel learning from the clinic and lab

Date: 29 October, 2020

Time: 5.15pm (GMT)

Event organised by Markets and Markets


Our Science

CAR T cells are genetically altered immune cells engineered to hunt down and destroy cancer cells.

Parallel CAR T Cell Platform

Leucid has developed a proprietary engine that develops CAR T molecules designed to be in more natural biological cell configurations. These are called parallel CAR T or pCAR T therapies. The pCAR T model has consistently outperformed previous generations of CAR T therapies in pre-clinical studies by enhancing T cell potency and generating a persistent long-term response.

T4 Immunotherapy

Leucid’s first clinical asset is a pan-ErbB targeted autologous CAR T cell product for patients with otherwise untreatable head and neck cancer. It is currently in Phase I and 16 patients have been treated at doses of up to 1 billion CAR T cells of whom 10 have achieved disease stabilisation. 

Novel Manufacturing Platforms

Leucid has developed an improved, more rapid and scalable manufacturing route that relies on a simple blood draw.


3rd Floor, Bermondsey Wing
Guys Hospital


© Leucid Bio Ltd

Contact Us